Last updated 18 days ago

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

600 patients around the world
Available in Spain, Mexico, United States
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease). Rimegepant will be further evaluated in this population with as needed use in a 12-week, open-label extension study.
Pfizer
4Research sites
600Patients around the world
This study is for people with
Migraine
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro de Investigación Médica Aguascalientes - CIMA
Centro de Investigación Médica Aguascalientes - CIMA
Av Independencia 2130, Trojes de Alonso, Aguascalientes
Clinstile S.A de C.V.
Durango 325, Roma Norte, Ciudad de México
Clinical Research Institute S.C.
Blvd. Manuel Ávila Camacho 1994, Colonia San Lucas Tepetlacalco, Tlalnepantla de Baz, Ciudad de México
Unidad de Investigación en Salud de Chihuahua S.C
Av. Renato Leduc No.151, Interior 4 Col. Toriello Guerra
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy